Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients

Basit Öğe Kaydı
dc.authoridBİÇİM, SOYKAN/0000-0001-7498-344X
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridBahçecioğlu, Ömer Faruk/0000-0002-4045-4555
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridGOK, Selim/0000-0003-3179-1899
dc.authorwosidBİÇİM, SOYKAN/ACZ-6163-2022
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidBahçecioğlu, Ömer Faruk/AAA-7477-2021
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorSarici, Ahmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBahcecioglu, Omer Faruk
dc.contributor.authorGok, Selim
dc.contributor.authorKuku, Irfan
dc.contributor.authorBicim, Soykan
dc.contributor.authorBerber, Ilhami
dc.date.accessioned2024-08-04T20:50:15Z
dc.date.available2024-08-04T20:50:15Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground and objective: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment approach in most multiple myeloma (MM) patients. Before ASCT, chemomobilization or only granulocyte-colony stimulating factor (G-CSF) mobilization can be preferred in stem cell mobilization. The primary aim of the study is to compare the effect of the two mobilization regimens on hematopoietic engraftment times, CD34+cell counts and number of apheresis required to harvest stem cells. Materials and methods: The records of MM patients who applied to our hospital between 2010 and 2020 were analysed retrospectively. Patients were divided into two groups (Group A: Cyclophosphamide plus filgrastim, Group B: Filgrastim alone) according to the mobilization regimen. Results: A total of 223 MM patients were included in this study (Group A:153, Group B:70 patients). When the patients in Group A and Group B were compared, the number of collected CD34+ cells were higher in Group A (p < 0.001). However, there was no significant difference between the two groups in terms of median times to neutrophil and platelet engraftment, and number of apheresis required to harvest stem cells (p > 0.05). The rate of infection development during mobilization in the patients in group A and the duration of hospitalization of these patients were higher than the patients in group B (p < 0.001). Patients receiving >6 cycles of chemotherapy and immunomodulatory treatment had lower collected CD34+ cells than other patients (p = 0.012 and p = 0.054). Conclusion: Based on our findings, filgrastim alone seems to provide a sufficient amount of stem cells in MM patients.en_US
dc.identifier.doi10.1016/j.transci.2021.103159
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue4en_US
dc.identifier.pmid34034961en_US
dc.identifier.scopus2-s2.0-85106366053en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103159
dc.identifier.urihttps://hdl.handle.net/11616/99948
dc.identifier.volume60en_US
dc.identifier.wosWOS:000709808800009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemomobilizationen_US
dc.subjectCyclophosphamideen_US
dc.subjectFilgrastimen_US
dc.subjectMultiple myelomaen_US
dc.subjectAutologous stem cell transplantationen_US
dc.titleFilgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu